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site occurred in 3 (3%) of patients in the NTC group, all requiring
catheter removal, and in 15 (16%) of patients in the TC group,
with 8 requiring catheter removal (bleeding was controlled in the
remaining patients using local pressure at the catheter entrance
site). The use of dual-lumen, tunneled, cuffed catheters for patients
with AL amyloidosis undergoing AuSCT appears to reduce the
incidence of CR-BSI and VT. However, catheter site bleeding
complications are higher and warrants further investigation.
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CRYOTHERAPY (ICE CHIPS) IS EFFECTIVE IN PREVENTING MELPHA-
LAN-INDUCED ORAL MUCOSITIS (OM) IN PATIENTS WITH AL AMY-
LOIDOSIS
Finn, K.T., Sanchorawala, V., Kunz, R., Seldin, D., Wilkes, G., Oran,
B. Boston Medical Center, Boston, MA
OM is a frequent complication following high dose melphalan
chemotherapy due to its cytocidal effect on normal, rapidly divid-
ing cells in the oral mucosa. Unfortunately, OM commonly pre-
cedes or occurs at the same time as chemotherapy-induced myelo-
suppression, placing patients at high risk for systemic infection,
longer hospital admissions, malnutrition, poor quality of life and
increased morbidity and mortality. In order to identify incidence of
OM and protection from cryotherapy, a retrospective analysis was
conducted at BMC to identify the incidence of OM as deﬁned by
SWOG criteria grade 2 or (moderate, severe or life-threatening)
in 179 patients with AL amyloidosis who received Melphalan
200mg/m2 in 2 divided doses over 2 days, followed by stem cell
rescue. 25 patients received cryotherapy (entire mouths cooled
using ice chips) 10 minutes before, all during and for 10 minutes
after melphalan infusion and 154 patients did not receive cryother-
apy. All patients followed the same mouth care regimen beginning
the ﬁrst day of melphalan (baking soda, antibacterial mouth rinses,
nystatin swish and swallow). Patients without cryotherapy treat-
ment were 10 times more likely (OR  10, 95% CI  2.59-38.46,
p  0.001) to develop OM (n  94) than those that did receive
cryotherapy (n  4). We found no difference in incidence of OM
if stem cells were infused between 24-48 hours after melphalan
(P  0.33) but found that patients were 6.25 times more likely
(95% CI 1.31-29.75, p 0.02) to develop OM if stem cells were
infused 72 hours later. Patients with pre-treatment creatinine levels
between 1.20-1.99mg/dl were 2.56 times more likely (95% CI 
1.11-5.93, p 0.03) and patients with creatinine 2.0 mg/dl were
5.79 times more likely (95% CI  1.08-31.07, p  0.04) and
patients on hemodialysis were 5.96 times more likely (95% CI 
1.01-35.57, p  0.05) to develop OM as compared to those with
normal creatinine levels. Patients who experienced vomiting were
3.11 times more likely (95% CI  1.53-6.33, p  0.002) to develop
OM. Oral cryotherapy is effective in reducing the incidence of OM
resulting from high dose melphalan in patients with AL amyloidosis.
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ROLE OF LOW-DOSE HEPARIN, URSODIOL AND GLUTAMINE IN PRE-
VENTING VENO-OCCLUSSIVE DISEASE OF THE LIVER IN ADULTS UN-
DERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
Desai, M.R., McCreary, E.L., Focazio, B., Devoe, C., John, V.S., Bayer,
R.-L. North Shore University Hospital, NYU School of Medicine,
Manhasset, NY
The clinical syndrome of veno-occlusive disease (VOD) of the
liver after hematopoeitic stem cell transplant (HSCT) is charac-
terized by jaundice, painful hepatomegaly and ﬂuid retention with
weight gain. Cytoreductive chemotherapy is felt to be the primary
cause of VOD, along with other risk factors. The incidence of
VOD in adults undergoing HSCT ranges between 25% to 65%.
VOD is considered to be the third leading cause of mortality (3%
to 67%) after GVHD and infection in HSCT patients. The patho-
physiology of VOD is not clear but the underlying mechanism is
felt to be due to high dose chemotherapy causing endothelial injury
of the sinusoids and small hepatic venules. This endothelial injury
induces a local hypercoagulable state by activating the coagulation
cascade and favoring clot formation. Fibrin related aggregates and
entrapment of ﬂuid and cellular debris occlude the small pores that
perforate the endothelial lining. This causes hepatic venous out-
ﬂow obstruction that generates a post sinusoidal intrahepatic portal
hypertension which is responsible for the clinical features of VOD.
Low dose heparin has been used as an anticoagulant in the pro-
phylaxis of VOD. Ursodiol, a hydrophilic nonhepatotoxic bile salt,
may be beneﬁcial in VOD prevention as it may replace more toxic
bile salts preventing damage by cholestasis. Glutathione (GSH), a
biosynthetic derivative of glutamine, is depleted during chemo-
therapy. Supplemental glutamine has been shown to preserve GSH
concentration thereby preventing hepatocellular damage seen in
VOD. Based on this information, we conducted a retrospective
study looking at 92 patients in our institution from January 2002 to
present who were treated with low dose heparin infusion (100
units/kg/day), ursodiol (300 mg po bid), and glutamine (7.5 gms po
bid). This regimen was started on the day of admission and dis-
continued prior to discharge. We reviewed the signs and symptoms
of VOD using the Seattle criteria. Hepatic doppler was obtained to
document reversal of ﬂow in hepatic and portal venous circulation.
The patient characteristics are shown in the table below. Out of 92
patients, 2 (2%) developed signs and symptoms consistent with
VOD with negative color doppler studies. Both of the patients
received allogeneic sibling transplants. Our experience demon-
strates a relatively low incidence of VOD in HSCT patients with
the above prophylactic regimen and we recommend its use.
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CLINICAL EVALUATION OF THE ADVERSE EFFECTS OF VORICONAZOLE
IN THE MANAGEMENT OF HEMOPOEITIC STEM CELL TRANSPLANT
PATIENTS
Li, H., Mazj, S., John, V., Focazio, B., Devoe, C., Bayer, R.-L. North
Shore University Hospital, NYU School of Medicine, Manhasset, NY
Fungal infection is one of the most important causes of morbidity
and mortality in hemopoeitic stem cell transplant (HSCT) recip-
ients. The growing incidence of fungal infection is related to
several factors including prolonged granulocytopenia, use of
broad-spectrum antibiotics, conditioning regimens, and use of im-
munosuppression to avoid graft-versus-host disease. Amphotericin
B with or without 5-ﬂucytosine is considered the standard therapy
for acute candidiasis with ﬂuconazole as an alternative. Amphoter-
icin B is also the ﬁrst-line therapy for invasive aspergillosis in
neutropenic patients. However nephrotoxicity is a major side effect
of amphothericin B, particularly in patients with HSCT needing
cyclosporine concurrently with amphotericin B. Both of these
drugs are nephrotoxic and impaired renal function may be ob-
served. Even with the development of the liposomal formulations
of amphotericin B, there is still about a 20% risk of nephrotoxicity.
Possible liposomal amphotericin B-induced nephrogenic diabetes
insipidus has also been reported. Third generation triazoles have
become available and have broadened the spectrum of effects
against invasive aspergillosis. The efﬁcacy of voriconazole (VRC)
in the treatment of invasive aspergillosis in patients with acute
myeloid leukemia undergoing HSCT has been reported. However
there is no report regarding the adverse effects of VRC in the
management of HSCT patients (PubMed Jan. 2001-Oct. 2003).
Therefore we conducted this retrospective study to assess the
adverse effects of VRC in HSCT patients (Jan. 2002 to Oct. 2003)
and to evaluate the safety of the empiric use of VRC in HSCT
patients. A total of 31 patients post HSCT received VRC. The
characteristics of the patients are shown in table.1. All adverse
events and laboratory abnormalities during treatment and follow-up
Table. Patient Characteristics
Age Median 48 years Range 22-66 years
Sex/(N) 92 Male 57 Female 35
Diagnosis Leukemia/lymphoma
38/27
Multiple myeloma/
solid tumors 25/2
Type of transplant Autologous 77 Allogeneic 15
Conditioning
regimen
Chemotherapy with total
body irradiation 9
Chemotherapy 83
MDS, myelodysplastic syndrome.
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